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Abstract
Background:  Hepatic  osteodystrophy  is  any  bone  disease  in  patients  with  chronic  liver  disease.
To measure  bone  mineral  density  (BMD)  T-score  by  bone  densitometry  (BD)  is  used,  classifying
the disease  in  osteopenia,  osteoporosis  and  severe  osteoporosis.  There  are  not  criteria  for
monitoring  and  detection  of  osteodystrophy  in  cases  of  non-cholestasic  cirrhosis.  To  determine
the risk  of  fracture  at  10  years,  Fracture  Risk  Assessment  Tool  (FRAX),  could  be  useful.
Objectives:  Determine  the  frequency  of  hepatic  osteodystrophy  in  cirrhotic  patients  according
to BD  and  FRAX  and  identify  associated  risk  factors.
Patients  and  methods: An  observational,  analytic,  cross-sectional  study.  We  included  cirrhotic
patients with  report  of  DO  and  FRAX.
Results:  52  patients  were  included,  38  were  female  (73.1%).  The  mean  age  was  12.29  ±  55.46
year-old, MELD  4.14  ±  11.71.  In  cholestatic  etiology  Mayo  Score  was  2.9  ±  3.31.  The  BMD  was
0.756 ±  0.1896  mg/  cm  2  and  T-score  -2.34  ±  1.0.  Of  all  patients,  26  (50%)  had  ranges  of  osteope-
nia and  21  (40.4%)  of  osteoporosis.  Fracture  risk  with  FRAX  10-year  was  7.77  ±  6,713,  and  when
we added  the  value  of  T-score  fracture  risk  was  13.72  ±  12.  Higher  prevalence  of  cholestatic
diseases in  women  and  viral  etiology  in  men  (P  =  0.006)  was  observed.  There  was  signiﬁcant
relationship  between  cholestatic  etiology  T-score,  alkaline  phosphatase,  and  elderly  and  FRAXS
with T-score  (P  =<  0.05).  Vitamin  D  was  lower  in  patients  with  cholestatic  liver  disease  (P  =  0.047)
and a  trend  towards  lower  value  of  FRAX  in  patients  with  cholestatic  liver  disease  was  observed.
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Conclusions:  The  frequency  of  osteoporosis  or  osteopenia  is  90.4%  in  Mexican  patients  with
liver cirrhosis  of  different  etiologies.  The  decreased  levels  of  bone  alkaline  phosphatase  and  25-
hydroxyvitamin-D  were  correlated  with  the  risk  of  bone  disease  in  patients  with  liver  cirrhosis.
© 2014  Sociedad  Médica  del  Hospital  General  de  México.  Published  by  Masson  Doyma  México
S.A. All  rights  reserved.
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Osteoporosis  y  riesgo  FRAX  en  pacientes  con  cirrósis  hepática
Resumen
Antecedentes:  La  osteodistroﬁa  hepática  es  cualquier  enfermedad  ósea  en  pacientes  con  enfer-
medad hepática  crónica.  Para  medir  la  densidad  mineral  ósea  (DMO)  se  utiliza  la  escala  T-score
por Densitometría  ósea  (DO)  clasiﬁcando  la  enfermedad  en  osteopenia,  osteoporosis  y  osteo-
porosis severa.  No  hay  criterios  establecidos  para  el  seguimiento  y  detección  de  osteodistroﬁa
en cirrosis  de  causa  no  colestásica.  Para  determinar  el  riesgo  de  fractura  a  10  an˜os,  el  Fracture
Risk Assessment  Tool  (FRAX),  podría  ser  útil.
Objetivo:  Conocer  la  prevalencia  de  osteodistroﬁa  hepática  en  pacientes  cirróticos  de  acuerdo
a DO  y  FRAX,  e  identiﬁcar  factores  de  riesgo  asociados.  Pacientes  y  Métodos:  Estudio  observa-
cional, analítico  y  transversal.  Incluimos  pacientes  cirróticos  con  reporte  de  DO  y  FRAX.
Resultados:  Se  incluyeron  52  pacientes,  38  (73.1%)  fueron  mujeres.  La  edad  promedio  fue
55.46 ±  12.29  an˜os,  MELD  11.71  ±  4.14,  en  etiología  colestásica  el  Mayo  Score  fue  2.9  ±  3.31.
La DMO  0.756  ±  0.1896  mg/cm2  y  T-score  -2.34  ±  1.0.  Tuvimos  26  pacientes  (50%)  con  osteope-
nia y  21  (40.4%)  con  osteoporosis.  El  riesgo  de  fractura  a  10  an˜os  por  FRAX  fue  7.77  ±  6.713,
que aumento  a  13.72  ±  12  al  considerar  FRAX  más  T-score.  Hubo  mayor  prevalencia  de  enfer-
medades colestásicas  en  mujeres  y  virales  en  hombres  (P  =  0.006).  Hubo  relación  entre  etiología
colestásica  y  T-score,  fosfatasa  alcalina,  edad  avanzada  y  FRAXS  más  T-score  (P  =  <0.05).  La  25-
hidroxivitamina  D  fue  menor  en  pacientes  con  hepatopatías  no  colestásicas  (P  =  0.047)  y  se
observó una  tendencia  a  menor  valor  de  FRAX  en  pacientes  con  colestasis.
Conclusión:  La  frecuencia  de  osteodistroﬁa  fue  de  90.4%.  Los  niveles  disminuidos  de  fosfatasa
alcalina ósea  y  de  25-hidroxivitamina-D  se  relacionaron  con  riesgo  de  osteodistroﬁa  en  pacientes
cirróticos.
© 2014  Sociedad  Médica  del  Hospital  General  de  México.  Publicado  por  Masson  Doyma  México
S.A. Todos  los  derechos  reservados.
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sseous  illness  in  patients  with  advanced  chronic  liver  dis-
ase  is  known  as  osteodistrophy  (OH),  mainly  including
steomalacy  and  osteoporosis.1 It  is  a  common  complication
f  liver  cirrhosis  that  can  worsen  after  hepatic  transplant
TH)  due  to  immunosuppression,  leading  to  a  signiﬁcant  risk
f  fractures,  with  impact  in  morbidity,  life  quality  and  even
urvivability.2 Osteoporosis  is  characterized  by  a  reduction
n  the  level  and  quality  in  the  osseous  mass,  associated  with
n  increased  risk  of  fractures  due  to  fragility.3 Diagnosis  is
etermined  by  measuring  the  osseous  mineral  density  (DMO)
nd  by  detecting  fractures.  A  value  inferior  to  -2.5  in  the  T
cale  indicates  osteoporosis  in  postmenopausal  women  and
n  men  older  than  50  years.  When  this  value  lies  within  -1  and
2.5,  it  is  classiﬁed  as  osteopenia  or  reduced  osseous  mass.4
he  probability  that  a  50  year  old  person  develops  a  hip
racture,  is  14%  in  women  and  5-6%  in  men.  The  risk  of  verte-
ral  deformity  is  25%  in  postmenopausal  women.5 Different
revalence  rates  in  osteoporosis  have  been  found,  accord-
ng  to  the  cirrhosis  aetiology:  For  viral  hepatitis  C  50%,  for
s
m
D
Diral  hepatitis  B  10%,  in  alcoholic  hepatopathy  30%  and  in
elf  immune  disease  between  12-55%  in  different  series.6
steomalacy  is  linked  to  cholestasis  disease  such  as  Primary
iliary  Cirrhosis  (CBP)  and  Sclerosing  Cholangitis  (CE).  Osteo-
orosis  in  patients  with  hepatic  conditions  involves  mainly
he  trabecular  bone,  characterized  by  a  decrease  in  DMO,
oor  functioning  of  osteoblasts,  an  augmentation  in  osteo-
lastic  cells  activities  and  low  levels  of  osteocalcine.  It  is
nown  that  osteoporosis  is  directly  related  with  the  type,
everity  and  progression  of  hepatic  disease.7 In  cirrhotic
atients  there  is  a  diminishment  of  25  D  hidroxi-vitamin  and
.25  D  dihidroxi-vitamin,  with  a  loss  in  DMO  more  frequently
n  the  spine.  In  percentages  of  osteopenia  and  osteoporo-
is,  according  to  the  European  Osteoporosis  Foundation,  the
ational  Osteoporosis  Foundation  of  the  US,  and  the  World
ealth  Organization,  four  categories  for  diagnosis  have  been
stablished:  (T-score)  normal:  DMO  not  higher  than  one
tandard  deviation  (DE)  lower  than  T-score.  Low  osseous
ass  or  osteopenia:  DMO  higher  than  1  but  lower  than  2.5
E  under  the  T-score.  Osteoporosis:  DMO  higher  than  2.5
E.  Severe  or  Established  Osteoporosis:  DMO  higher  than  2.5
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expressed  as  proportions  and  percentages,  numerical  as
mean  and  standard  deviation.  For  comparison  betweenOsteoporosis  and  FRAX  risk  in  patients  with  liver  cirrhosis  
and  1  or  more  vertebral  compression  fractures,  with  annual
follow  up  in  patients  with  risk  factors  and  otherwise  every
2  or  3  years.8 In  patients  with  chronic  cholestasis,  osteo-
porosis  has  been  reported  in  women  in  37%.  In  India  in  2009
there  was  a  report  of  68%  of  cirrhotic  patients  due  to  viral
infection.  In  the  patients  with  B  hepatitis  the  prevalence
was  of  68%  and  100%  in  patients  with  C  hepatitis.  Caused
by  alcohol  a  prevalence  of  56.7%  was  found.  There  has  also
been  research  in  the  relation  between  antiretroviral  ther-
apy  against  hepatitis  and  the  development  of  osteopenia,
without  any  concluding  evidence.9 Most  of  the  patients  with
hepatic  transplant  had  a  fast  loss  in  osseous  mass  during  the
ﬁrst  6  months  after  the  transplant,  reaching  6%  in  lumbar
spine  in  3 months.10 Studies  have  shown  low  osteocalcine
serum  values  (mark  protein  of  the  osteoblastic  function)
and  reduction  in  trophic  factors  such  as  grow  factor  similar
to  insulin  (IGF-1).  A  reduction  in  IGF-1  has  been  described
in  cirrhotic  patients.  Studies  have  shown  that  the  admin-
istration  of  IGF-1  increase  the  osseous  mass  and  the  DMO
in  cirrhotic  rats.11 In  cholestasis  hepatopathies  it  is  related
with  the  increase  in  bilirubin  and  biliary  acids,  as  a con-
sequence  of  cholestasis  or  of  the  hepatic  disease  in  the
development  of  osteodistrophy  due  to  the  harmful  effect
of  not  conjugated  bilirubin  over  the  osteoblastic  cell  viabil-
ity  and  proliferation.  However,  this  has  been  questioned  by
studies  made  in  populations  with  Gilbert  Syndrome,  where
no  association  was  found.  Yet,  the  harmful  effect  of  biliru-
bin  has  to  be  evaluated  within  a  global  context  of  hepatic
disease,  with  simultaneous  increase  in  biliary  acids,  inﬂam-
matory  cytokines  and  in  the  state  of  the  phosphocalcic
metabolism,  including  D  vitamin  and  parathyroid  hormone.12
Lithocholic  Acid  (LCA),  same  as  D  vitamin,  is  an  antagonist  of
the  vitamin  D  receptor  (VDR).13 The  LCA  reduced  the  vitamin
D  capacity  of  activating  genes  involved  in  the  metabolism  of
vitamin  D.  Hence,  the  increase  in  lithocolic  acid,  second  to
cholestasis,  would  interfere  with  vitamin  D  in  its  receptive
level  and  would  diminish  the  expression  of  genes  related  to
the  osseous  formation.  This  has  been  related  with  increased
intensity  in  patients  with  hepatic  insufﬁciency  accompanied
by  hypoalbuminemia.14
In  chronic  hepatic  disease,  the  complete  study  with
radiography  of  the  dorsal  and  lumbar  spine,  in  lateral
projection,  to  identify  previous  fractures.  Calcium  levels
(corrected  with  albumin),  phosphor,  25-hidroxivitamin  D,  of
parathyroid  hormone,  renal  function.  Biochemical  marks  of
osseous  interchange  are  used  to  value  the  response  to  treat-
ment:  alkaline  phosphatase,  serum  osteocalcine,  peptide
serum  of  procollagen  type  1  (formation),  N-telopeptide,  C-
telopeptide  and  desoxiporidonoline  (resorption).  However,
they  can  be  modiﬁed  by  hepatic  ﬁbrosis.  If  osteomalacy
is  suspected  by  defect  in  the  mineralization,  a  trans-iliac
biopsy  is  indicated.  Osseous  densitometry  (DO)  in  patients
with  advanced  cirrhosis,  ascites  higher  than  4  litres  can
give  false  positives.15 A  study  in  patients  with  hepatopathic
cholestasis  identiﬁes  polymorphism  COLIA1  as  a  genetic
marker  of  osseous  mass  in  postmenopausal  female  patients
with  CBP  and  osteoporosis.  COLIA1  Sp1  could  identify  sub-
groups  of  patients  with  CBP  before  the  development  of
osteoporosis.16 In  the  actuality  the  realisation  of  DO  by  DEXA
has  not  been  enough  to  identify  persons  with  risk  of  frac-
ture  due  to  speciﬁc  measurements  that  lack  sensibility.  Dr.
Kanis  and  collaborators,  carried  out  a  meta-analysis,  with
g
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he  purpose  of  identifying  the  risk  values  independent  of  the
MO.  From  the  outcomes  resulted  the  FRAX  tool  (Fracture
isk  Assessment  Tool):  a  model  that  allows  the  prediction
f  the  absolute  risk  of  osteoporotic  fracture  in  10  years,
ntegrating  clinical  risk  factors  and,  if  available,  the  results
f  the  DMO;  classifying  people  with  greater  risk  and  can-
idate  to  treatment.  It  values  age,  gender,  corporal  mass
ndex,  antecedents  of  personal  fracture  and  femur  fracture
n  progenitors,  tobacco  and  steroids  use,  rheumatoid  arthri-
is  diagnosis,  secondary  osteoporosis  causes,  alcoholism  and
ptionally  the  T  index  value  of  the  femurs  neck,  measured
y  X-rays  DO  of  double  energy.  This  allows  to  calculate  the
bsolute  risk  of  proximal  femur  fracture  or  of  any  other
ayor  osteoporotic  fracture  in  the  following  10  years.  In  a
tudy  performed  in  Spain  in  2009,  it  was  concluded  that  the
isk  of  fracture  of  FRAX  is  higher  in  patients  that  received
revious  treatment  with  steroids.17 However,  it  has  never
een  used  to  evaluate  patients  with  hepatopathy,  consider-
ng  it  as  a  cause  of  secondary  osteoporosis.  This  tool  helps
n  the  taking  of  decisions  and  stems  from  the  necessity  of
aking  out  complementary  accessory  tests  or  the  indication
nd  necessity  of  pharmacological  treatment.
This  study  had  the  purpose  of  researching  the  preva-
ence  of  hepatic  osteodistrophy  in  a  sample  on  cirrhotic
atients  of  the  Mexico  General  Hospital  (MHG),  according
o  the  DMO  y  FRAX  risk,  and  to  identify  the  associated  risk
actors.
atients and methods
 transversal  analytic  study  was  conducted,  in  which  the
linical  expedients  of  cirrhotic  patients  of  MHG  and  the
ndividual  risk  of  FRAX  fracture  was  calculated.  This  study
ncluded  patients  with  diagnosis  of  cirrhosis  whose  are
reated  in  the  clinic  of  the  MHG  with  DO.  We  recorded
hether  there  was  a  history  of  hip  fracture  or  vertebral  col-
mn  or  any  previous  fracture.  Individual  FRAX  fracture  risk
ith  validated  computer  tool,  which  ultimately  yields  the
isk  of  10-year  fracture  and  T-score  values  were  obtained  by
D  was  calculated.  Patients  with  antecedents  of  cirrhosis
hat  had  had  an  hepatic  transplant,  chronical  renal  disease
nd  hypogonadism,  thyroidal  disease,  cirrhosis  of  autoim-
une  nature  that  had  received  treatment  with  steroid,
ther  pathologies  of  autoimmune  origin  or  hepatic  cirrhosis
ue  to  infection  by  VHC  that  are  taking  antiviral  treat-
ent,  have  been  excluded.  The  statistical  analysis  was
one  in  accordance  to  the  variables  and  parametric  and
on-parametric  tests  were  applied,  for  the  description  of
ariables,  measures  of  central  tendency  and  dispersion  were
ade.  T  student  test  was  used  for  quantitative  variable  and
2  for  qualitative.  2  ways  ANOVA  was  used  for  the  analysis
etween  groups,  considering  a  value  of  P  <  0.05  statistically
igniﬁcant.
Statistical  analysis:  The  qualitative  variables  wereroups,  Student’s  t  test  was  used  for  quantitative  and
ualitative  variables  X2.  To  evaluate  correlation  between
ariables  correlation  coefﬁcient  r2  of  Pearson  was  used.  A
alue  of  P  <  0.05  was  considered  statistically  signiﬁcant.
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Table  1  Clinical  features  in  hepatopaties  by  colestatic  and  no  colestatic  illness.
Colestatic  No-Colestatic  P
BMI  23.08  ±  3.98 26.07  ±  3.60  0.006
MELD 11.12  ±  4.42  12.26  ±  3.86  0.327
DMO 0.778  ±  0.127  .735  ±  0.233  0.411
T-SCORE -2.20  ±  0.944  2.47  ±  1.05  0.328
R-FRAX 8.84  ±  8.48  6.78  ±  4.45  0.273
FRAX HIP  3.02  ±  5.56  1.330  ±  1.22  0.148
FRAX T-SCORE  11.18  ±  7.97  16.07  ±  14.60  0.145
FRAX T-SCORE  HIP  4.44  ±  5.69  9.21  ±  13.03  0.091
BONE ALKALINE  PHOSPHATASE  (U/L) 53.06  ±  27.83 65.27  ±  25.97 0.0108
 12.
R
D
F
o
o
t
t
p
o
t
i
c
a
T
(
w
m
t
d
v
(
t
n
(
w
g
i
b
6
U
l
1
O
T
2
r
w
p
t
7
w
w
1
e
(
m
w
I
r
a
l
c
a
p
a
m
b
e
p
a
c
h
D
D
h
(
a
e
p
t
p
t
a
b
r
ﬁ
aVITAMIN D 17.97  ±
esults
emographic  and  biochemical  characteristics
ive  hundred  expedients  of  the  Gastroenterology  Service,
f  the  Transplant  Clinic,  and  the  Liver  Clinic  were  assessed,
f  which  52  patients  fulﬁlled  the  criteria  of  inclusion  to
he  study.  The  average  age  was  55.46  ±  12.29  years.  Of
hem  38  were  women  (73.1%)  and  14  men  (26.9%).  All  the
atients  fulﬁlled  the  biochemical  and  by  ultrasound  criteria
f  hepatic  cirrhosis.  The  different  aetiologies  of  cirrhosis
hat  were  found,  were:  alcohol  in  6  patients  (11.5%),  viral
n  6  patients  (11.5%),  autoimmune  in  5  patients  (9.6%),
holestasis  disease  in  25  (48.1%),  non-alcoholic  steatohep-
titis  (EHNA)  in  5  (9.6%)  and  idiopathic  in  5  patients  (9.6%).
he  gravity  of  the  disease  was  evaluated  with  the  Child  Pugh
Child)  scale,  9  (17.3%)  patients  were  Child  A,  20(38.5%)
ere  Child  B  and  21  (40.4%)  were  Child  C.  The  MELD
ean  was  11.71  ±  4.14  and  for  the  cholestasis  origin  causes
he  Mayo  Score  was  calculated,  which  was  2.9  ±  3.31.  The
ata  of  portal  hypertension  by  endoscopy  with  oesophageal
arices  and  ultrasound  ﬁndings,  corresponded  to  32  patients
61.5%).  According  to  the  nutritional  state  of  the  popula-
ion,  the  body  mass  index  (BMI)  was  classiﬁed  in  different
utritional  ranges,  1  patient  (1,9%)  with  underweight,  25
48.1%)  patients  within  the  normal  parameters,  21  (40.4%)
ith  overweight,  4  (7.7%)  with  grade  I  obesity,  1  (1,9%)  with
rade  II  obesity  and  no  patient  in  grade  III.  The  serum  stud-
es  of  importance  were:  Albumin  2.971  ±  0.7261  g/dl,  total
ilirubin  2.47  ±  0.21  mg/dl,  aspartate  aminotransferase
6.27  ±  46.83  U/L,  alanine  aminotransferase  60.27  ±  46.81
/L,  gamma-glutamiltransferase  190.31  ±  0.75  U/L,  alka-
ine  phosphatase  228.29  ±  186.47  U/L,  lactic  dehydrogenase
73.85  ±  3.15  U/L.
sseous evaluation
he  average  of  DMO  was  0.756  ±  0.1896  mg/cm2,  T-score  -
.34  ±  1.0.  Of  which  5  patients  (9.6%)  were  inside  normal
anges,  26  (50%)  within  osteopenia  ranges  and  21  (40.4%)
ithin  osteoporosis  ranges.  Of  these  patients  with  osteo-
orosis,  11  (21%)  had  a  history  of  bone  fracture.  Calculating
he  risk  of  fracture  in  10  years  with  FRAX,  this  was  of
.77  ±  6.713,  when  added  the  T-score,  the  risk  of  fracture
as  13.72  ±  12.  The  values  of  osseous  alkaline  phosphatase
f
s
s
e76 11.17  ±  10.54 0.047
ere  in  average  59.40  ±  27.32  and  of  25-hidroxivitamin  D
4.44  ±  12.4.
In  our  population,  a  higher  prevalence  of  cholestasis  dis-
ases  was  found  in  women  and  the  viral  aetiology  in  men.
P  =  0.006).  Alcohol  consumption,  viral  infection,  autoim-
une  disease,  cholestatic  origin,  NASH  or  cryptogenic  or
ere  not  correlated  risk  factor  for  hepatic  osteodystrophy.
n  the  cluster  analysis  according  values  MELD  or  Child  no  cor-
elation  was  found  with  increased  risk  of  FRAX.  (r2  = 0.187
nd  0.115;  P  =  0.18  and  0.41  respectively).
Because  in  several  publications  there  is  a  higher  preva-
ence  in  aetiology  cholestasis,  an  analysis  by  aetiology  was
arried  out,  ﬁnding  a  highly  signiﬁcant  relation  between
etiology  cholestasis  and  T-score,  osseous  alkaline  phos-
hatase,  age  and  FRAXs,  with  T-Score  (P  <  0.05).  Analysis  by
etiology  did  not  show  differences  in  the  values  of  osseous
ineral  density,  T-score  and  risk  FRAXs.
The  IMC  was  lower  in  patients  with  hepatopathy  caused
y  cholestasis  than  other  reasons  with  a  relevant  differ-
nce  (P  =  0.006).  The  levels  of  vitamin  D  were  the  lowest  in
atients  with  non-cholestasis  hepatopathies  (P  =  0.047)  and
 tendency  to  a  lower  FRAX  level  can  be  seen  in  patients  with
holestasis  hepatopathy.  The  ﬁndings  in  groups  of  cholestasis
epatopathy  y  non-cholestasis  can  be  seen  in  Table  1.
iscussion
uring  the  revision  of  the  expedients  very  few  patients
ad  studies  that  evaluated  the  osseous  metabolism
osseous  alkaline  phosphatase,  25-hidroxivitamin  D,  DMO
nd  parathyroid  hormone)  probably  because  there  is  no
stablished  criteria  during  the  evaluation  of  cirrhotic
atients  to  assess  osseous  disease.  All  this  contributes  to
he  pathology  osteodystrophy  is  undervalued  in  the  cirrhotic
atient.  Particularly  in  the  case  of  our  hosptalaria  Institu-
ion,  besides;  DO  is  not  available.  Most  of  our  patients  had
 diagnosis  of  cholestatic  diseases  (48.1%),  this  most  likely
ecause  there  are  speciﬁc  guidelines  for  primary  biliary  cir-
hosis  and  primary  sclerosing  cholangitis  where  indicated
nding  conduct  BMD  or  osteopenia  osteoporosis  and  initi-
te  appropriate  treatment.  18-20  However,  in  our  study  we
ound  no  correlation  between  the  different  causes  of  cirrho-
is  and  increased  risk  of  fracture,  probably  due  to  the  small
ample  size  with  which  we,  therefore,  should  be  looking  to
xpand  the  sample  size  to  ﬁnd  associated  risk  factors.  It is
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known  that  the  risk  of  fracture  in  women  over  50  years  is
39%  and  men  13%.18 DO  was  also  identiﬁed  with  T-score  -
2.5  or  less  in  21%  of  white  women,  women  Mexico-American
and  16%  African  American  10%  and  20%  of  patients  with
vertebral  fracture  posmenoupáusicas.3,5,19 In  our  study,  73%
were  women,  many  of  them  postmenopausal,  these  factors
could  constitute  a  bias  for  themselves  increase  the  risk  for
bone  disease  in  our  patients.  On  the  other  hand,  particu-
larly  in  cirrhotic  patients,  factors  such  as  female  gender  and
older  than  50  years  should  be  considered  as  probable  indica-
tions  for  bone  disease  ﬁnding  in  cirrhotic  patients  regardless
of  etiology  it.  The  gravity  of  the  illness  was  measured  in
respect  to  MELD.  In  general  MELD  was  of  11.71,  which  indi-
cates  that  the  patients  have  a  mortality  of  6%  in  3  months.
This  model  was  created  for  the  assignment  of  organs  in  liver
transplant.20 Using  the  prognosticated  value  of  Child,  the
majority  (40.4%)  reached  Child  C  criteria  with  survivabil-
ity  of  45%  in  a  year  and  of  35%  in  2  years,  this  reﬂects  the
severity  of  illness  of  our  patients;  however,  no  correlation
between  the  severity  of  disease  or  MELD  Child  with  FRAX
risk  was  found,  perhaps  this  may  be  secondary  to  our  small
sample  size.
Hepatic  osteodistrophy  (deﬁned  as  any  osseous  disease
in  patients  with  advanced  hepatic  illness)21 was  found  in
the  90.4%  of  our  population.  This  prevalence  is  higher  than
reported  in  literature  in  almost  50%.22,23 26  patients  were
classiﬁed  with  osteopenia  (50%)  and  21  with  osteoporosis
(40.4%).  These  ﬁndings  in  the  diagnosis  of  hepatic  osteodis-
trophy,  show  that  a  minimum  of  90%  of  the  patients  must  be
under  treatment  and  vigilance  to  prevent  fractures.
In  the  cirrhotic  patients  the  FRAX  calculated  a frac-
ture  risk  of  7.77%  ±  6.713%  without  taking  into  account  DO
data.  If  added,  the  T-score  data  by  DO  raise  the  risk  to
13.72%  ±  12.03%.  It  should  be  noted  that  there  is  no  previ-
ous  literature  that  calculates  the  FRAX  risk  in  patients  with
hepatic  cirrhosis,  making  these  ﬁndings  notably  valuable.
Because  the  reported  prevalence  in  cholestasis  aetiology  is
higher24,  in  our  study  a  highly  signiﬁcant  relation  between
cholestasis  aetiology  with  T-score,  osseous  alkaline  phos-
phatase,  age  and  FRAX  with  T-score  was  found.  On  the  other
hand,  different  studies  have  demonstrated  that  cirrhosis,
caused  by  cholestasis  aetiologies,  is  associated  to  a  higher
risk  to  suffer  of  osteodistrophy  (37%).25,26 In  our  population
the  patients  with  cholestasis  aetiology  possess  higher  lev-
els  of  vitamin  D  when  compared  to  other  cirrhosis  causes
(p  =  0.047).  Probably  reﬂecting  a  deﬁcit  of  this  vitamin  in
cirrhotic  patients  for  other  causes  such  as  alcohol.
In  our  study  the  FRAX  risk  increase  was  associated  with
advanced  age.  This  relation  can  be  supported  by  signiﬁcant
statistic  results.
Currently  it  is  unknown  the  cut  point  of  the  FRAX  risk
at  which  osteoporosis  treatment  should  begin.  Comparing
the  fracture  risk  to  10  years  of  a  healthy  patient  of  0.10%
with  the  average  risk  of  our  population  of  7%,  it  could  be
suggested  the  realization  of  a  DO  to  value  treatment  and
continuous  vigilance  of  hepatic  osetodistrophy,  given  a  risk,
calculated  in  cirrhotic  patients,  using  a  FRAX  index  higher
than  2.This  is  the  ﬁrst  work  where  the  use  FRAX  index  is  pro-
posed  as  a  fracture  risk  mark  to  10  years  in  patients  with
hepatic  cirrhosis  of  any  aetiology.  More  studies  are  needed
to  continue  the  validation  of  this  tool.
1177
onclusions
his  study  shows  the  frequency  of  hepatic  osteodistrophy  of
0.4%  in  a  sample  of  Mexican  patients  with  hepatic  cirrhosis
f  different  aetiologies,  attending  to  the  Hospital  Gen-
ral  de  México.  There  are  no  differences  in  the  prevalence
f  hepatic  osteodistrophy  between  the  different  causes  of
irrhosis.  The  levels  of  osseous  alkaline  phosphatase  and
f  25-hidroxivitamin  D  correlated  with  the  risk  of  hepatic
steodistrophy  in  patients  with  cholestasis  aetiology.  The
ost  important  thing  should  be  the  identiﬁcation  of  patients
n  which  the  loss  of  life  quality  or  incapacity  can  be  pre-
ented.  Because  of  the  ﬁndings  of  this  study,  a  fracture  risk
o  10  year  calculated  in  the  ﬁrst  contact  interview  of  cir-
hotic  patients  with  the  FRAX  tool,  a  value  higher  than  2,
n  the  aforementioned  index,  could  be  proposed  as  a  cohort
oint  to  be  followed  by  DO  and  to  start  a  scheme  of  vigilance
nd  treatment.
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